Literature DB >> 11173615

Current Management of AIDS Related Non Hodgkin's Lymphoma.

Kathryn Fife1, Mark Bower.   

Abstract

Non Hodgkin's lymphoma is the AIDS defining illness in 3-3.5% of patients and is increasing in incidence as the survival of HIV infected people improves. The incidence of these intermediate/high grade B cell malignancies is sixty times higher than in the general population. The most important prognostic factors are a CD4 positive lymphocyte count of <100 cells/mm3, a prior AIDS defining diagnosis, an ECOG performance status >2 and primary cerebral origin. Patients with any of these factors are most likely to benefit from palliative rather than radical treatment. Good prognosis patients have a 30-40% chance of cure from their lymphoma with carefully administered intensive chemotherapy.

Entities:  

Year:  1996        PMID: 11173615     DOI: 10.1007/bf02904823

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

2.  Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma.

Authors:  J Gabarre; E Lepage; A Thyss; R Tubiana; Y Bastion; D Schlaifer; C Sebban; V Ribrag; M Fereres; M Raphael
Journal:  Ann Oncol       Date:  1995-12       Impact factor: 32.976

3.  Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients.

Authors:  E Vaccher; U Tirelli; M Spina; R Talamini; D Errante; C Simonelli; A Carbone
Journal:  J Clin Oncol       Date:  1996-08       Impact factor: 44.544

4.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

5.  Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen.

Authors:  J A Sparano; P H Wiernik; M Strack; A Leaf; N Becker; E S Valentine
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

6.  Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival.

Authors:  A M Levine; J Sullivan-Halley; M C Pike; M U Rarick; C Loureiro; M Bernstein-Singer; E Willson; R Brynes; J Parker; S Rasheed
Journal:  Cancer       Date:  1991-12-01       Impact factor: 6.860

7.  Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.

Authors:  J M Pluda; D J Venzon; G Tosato; J Lietzau; K Wyvill; D L Nelson; E S Jaffe; J E Karp; S Broder; R Yarchoan
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 9.  MGBG: teaching an old drug new tricks.

Authors:  D D Von Hoff
Journal:  Ann Oncol       Date:  1994-07       Impact factor: 32.976

10.  The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region.

Authors:  D Serraino; G Salamina; S Franceschi; D Dubois; C La Vecchia; J B Brunet; R A Ancelle-Park
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.